Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography

References

• Balis F. M. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clinical Pharmacokinetics 1986; 11: 222–235
   Web of Science ®Google Scholar
• Bender R. A., Hamel E., Hande K. R. Plant Alkaloids, in Cancer Chemotherapy: Principles and Practice, B. A. Chabner, J. M. Collins. Lippincott., Philadelphia 1990; 253–275
   Google Scholar
• BorÉ P., Rahmani R., Van Cantfort J., Focan C., Cano J. P. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Cancer Chemotherapy and Pharmacology 1989; 23: 247–251
   PubMed Web of Science ®Google Scholar
• Cannobio L., Boccardo F., Pastorino G., Brema F., Martini C., Resasco M., Santi L. Phase-II study of navelbine® in advanced breast cancer. Seminars in Oncology 1989; 16: 33–36, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Cros S., Wright M., Morimoto M., Lataste H., Couzinier J. P., Krikorian A. Experimental antitumor activity of navelbine®. Seminars in Oncology 1989; 16: 15–20, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Debal V., Morjani H., Millot J.-M., Angiboust J.-F., Gourdier B., Manfait M. Determination of vinorelbine (Navelbine) in tumour cells by high-performance liquid chromatography. Journal of Chromatography, Biomedical Applications 1992; 581: 93–99
   PubMed Web of Science ®Google Scholar
• Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., Dalphin J. C. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. American Journal of Clinical Oncology 1991; 14: 115–119
   PubMed Web of Science ®Google Scholar
• De Smet M., Van Belle S. J. P., Storme G. A., Massart D. L. High-performance liquid chromatographic determination of vinca-alkaloids in plasma and urine. Journal of Chromatography, Biomedical Applications 1985; 345: 309–321
   PubMed Web of Science ®Google Scholar
• Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annual Review of Biochemistry 1989; 58: 137–171
   PubMed Web of Science ®Google Scholar
• Ford J. M., Hait W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacological Reviews 1990; 42: 155–199
   PubMed Web of Science ®Google Scholar
• George M. J., Heron J. F., Kerbrat P., Chauvergne J., Goupil A., Lebrun D., Guastalla J. P., Namer M., Bugat R., Ayme Y., Toussaint C., Lhomme C. Navelbine® in advanced ovarian epithelial cancer: a study of the french oncology centers. Seminars in Oncology 1989; 16: 30–32, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Hillcoat B. L. Priorities in experimental therapeutics—a surfeit of riches. European Journal of Cancer and Clinical Oncology 1989; 25: 1263–1269
   PubMedGoogle Scholar
• Ihde D. C. Chemotherapy of lung cancer. New England Journal of Medicine 1992; 327: 1434–1441
   PubMed Web of Science ®Google Scholar
• Jehl F., Debs J., Herlin C., Quoix E., Gallion C., Monteil H. Determination of navelbine and desacetylnavelbine in biological fluids by high-performance liquid chromatography. Journal of Chromatography, Biomedical Applications 1990; 525: 225–233
   PubMed Web of Science ®Google Scholar
• Jehl F., Quoix E., LevÉQue D., Pauli G., Breillout F., Krikorian A., Monteil H. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high-performance liquid chromatography. Cancer Research 1991; 51: 2073–2076
   PubMed Web of Science ®Google Scholar
• Jehl F., Bresler L., Koechlin C., Merle-Melet M., Didelot J. P., Hazebroucq J. Pharmacokinetics and biliary elimination of temafloxacin in pigs. Journal of Antimicrobial Chemotherapy 1992; 30: 189–196
   PubMed Web of Science ®Google Scholar
• Juste C., Corring T., Le Coz Y. Bile secretion in the fistulated pig: effect of the method used for bile reinfusion. Reproduction, Nutrition, Développement 1983; 23: 765–773
   PubMedGoogle Scholar
• Keller R. P., Altermatt H. J., Donatsch P., Zihlmann H., Laissue J. A., Hiestand P. C. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16–213) enhance in vivo cytostatic activity and toxicity. International Journal of Cancer 1992; 51: 433–438
   PubMed Web of Science ®Google Scholar
• Krikorian A., Rahmani R., Bromet M., Bore P., Cano J. P. Pharmacokinetics and metabolism of navelbine®. Seminars in Oncology 1989; 16: 21–25, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Le Chevalier T., Pujol J. L., Douillard J. Y., Alberola V., Monnier A., RiviÈRe A., Lianes P., Chomy P., Cigolari S., Berthaud P., Gottfried M., Panizo A. G., Besenval M., Brisgand D. A European multicentre randomized study comparing navelbine alone vs navelbine—cisplatin vs vindesine—cisplatin in 612 patients with advanced non small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 1992; 11: 289
   Google Scholar
• LevÊQue D., Jehl F., Quoix E., Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. Journal of Clinical Pharmacology 1992b; 32: 1096–1098
   PubMed Web of Science ®Google Scholar
• LevÉQue D., Merle-Melet M., Bresler L., Didelot J. P., Aymard J. P., Wihlm J., Jehl F. Biliary elimination and pharmacokinetics of vinorelbine in micropigs. Cancer Chemotherapy and Pharmacology 1993b; 32: 487–490
   PubMed Web of Science ®Google Scholar
• LevÉQue D., Quoix E., Dumont P., Massard G., Hentz J. G., Charloux A., Jehl F. The pulmonary distribution of vinorelbine in patients with non small cell lung cancer. Cancer Chemotherapy and Pharmacology 1993a, in press
   Web of Science ®Google Scholar
• LevÉQue D., Wihlm J., Jehl F. Les interactions pharmacocinétiques des agents anticancéreux. Journal de Pharmacie Clinique 1992a; 11: 249–256
   Google Scholar
• Lum B. L., Kaubisch S., Yahanda A. M., Adler K. M., Jew L., Ehsan M. N., Brophy N. A., Halsey J., Gosland M. P., Sikic B. I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. Journal of Clinical Oncology 1992; 10: 1635–1642
   PubMed Web of Science ®Google Scholar
• Newell D. R. Pharmacokinetic determinants of the activity and toxicity of antitumor agents. Cancer Surveys 1989; 8: 557–603
   PubMedGoogle Scholar
• Nicot G., Lachatre G., Marquet P., Bonnaud F., Vallette J. P., Rocca J.-L. High-performance liquid chromatographic determination of navelbine in human plasma and urine. Journal of Chromatography, Biomedical Applications 1990; 528: 258–266
   PubMed Web of Science ®Google Scholar
• Pastan I., Gottesman M. Multiple-drug resistance in human cancer. New England Journal of Medicine 1987; 316: 1388–1393
   PubMed Web of Science ®Google Scholar
• Pastan I., Gottesman M. M. Multidrug resistance. Annual Review of Medicine 1991; 42: 277–286
   PubMed Web of Science ®Google Scholar
• Potier P. The synthesis of navelbine® prototype of a new series of vinblastine derivatives. Seminars in Oncology 1989; 16: 2–4, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Rahmani R., Gueritte F., Martin M., Just S., Cano J. P., Barbet J. Comparative pharmacokinetics of antitumor vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. Cancer Chemotherapy and Pharmacology 1986; 16: 223–228
   PubMed Web of Science ®Google Scholar
• Rahmani R., Bruno R., Iliadis A., Favre R., Just S., Barbet J., Cano J. P. Clinical pharmacokinetics of the antitumor drug navelbine (5′-noranhydrovinblastine). Cancer Research 1987; 47: 5796–5799
   PubMed Web of Science ®Google Scholar
• Ratain M. J., Schilsky R. L., Conley B. A., Egorin M. J. Pharmacodynamics in cancer therapy. Journal of Clinical Oncology 1990; 8: 1739–1753
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Donehower R. C. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacology and Therapeutics 1991; 52: 35–84
   PubMed Web of Science ®Google Scholar
• Singer W. D., Himes R. H. Cellular uptake and tubulin binding properties of four vinca alkaloids. Biochemical Pharmacology 1992; 43: 545–551
   PubMed Web of Science ®Google Scholar
• Solere P., Lucas C. Limites analytiques en pharmacocinétique clinique: l'exemple des vinca-alcaloïdes. Bulletin du Cancer 1991; 78: 775–787
   PubMed Web of Science ®Google Scholar
• Stewart D. J., Lu K., Benjamin R. S., Leavens M. E., Luna M., Yap H. Y., Loo T. L. Concentrations of vinblastine in human intracerebral tumor and other tissues. Journal of Neuro-Oncology 1983; 1: 139–144
   PubMed Web of Science ®Google Scholar
• Thierry A. R., Jorgensen T. J., Forst D., Belli J. A., Dritschilo A., Rahman A. Modulation of multidrug resistance in chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Communications 1989; 1: 311–316
   PubMedGoogle Scholar
• Van Belle S. J.-P., De Smet M., Monsaert C., Geerts F., Storme G. A., Massart D. L. High-performance liquid chromatographic determination of navelbine in MO4 mouse fibrosarcoma cells and biological fluids. Journal of Chromatography, Biomedical Applications 1992; 576: 351–357
   PubMed Web of Science ®Google Scholar
• Van Tellingen O., Beijnen J. H., Nooyen W. J. Analytical methods for the determination of vinca alkaloids in biological specimens: a survey of the literature. Journal of Pharmaceutical and Biomedical Analysis 1991; 9: 1077–1082
   PubMed Web of Science ®Google Scholar
• Van Tellingen O., Sips J. H. M., Beijnen J. H., Bult A., Nooijen W. J. Pharmacology bio-analysis and pharmacokinetics of the vinca alkaloids and semi-synthetic derivatives (review). Anticancer Research 1992a; 12: 1699–1716
   PubMed Web of Science ®Google Scholar
• Van Tellingen O., Kuijpers A., Beijnen J. H., Baselifr M. R. P., Burghouts J. T. M., Nooyen W. J. Bioanalysis of vinorelbine by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography, Biomedical Applications 1992b; 573: 328–332
   PubMed Web of Science ®Google Scholar